Ocular Toxicity of Mirvetuximab

Eleonora Corbelli, Elisabetta Miserocchi, Alessandro Marchese, Chiara Giuffrè, Luigi Berchicci, Riccardo Sacconi, Francesco Bandello, Giulio Maria Modorati

Research output: Contribution to journalArticlepeer-review


PURPOSE: To report the clinical features and outcomes of corneal toxicity following mirvetuximab soravtansine therapy. METHODS: Five patients who were treated with mirvetuximab soravtansine were evaluated in our hospital for ocular symptoms during a period of 5 months between December 2017 and April 2018. A complete ophthalmologic examination, including anterior segment infrared reflectance (AS-IR) and anterior segment optical coherence tomography (AS-OCT), was performed. RESULTS: All 5 patients were female (average age, 62.4 ± 5.5 years) and being treated for advanced epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer. Both eyes were involved in each case. Patients complained of blurred vision (n = 5), ocular pain (n = 2), tearing (n = 5), foreign-body sensation (n = 4), and photophobia (n = 4). Slit-lamp examination demonstrated fine corneal subepithelial opacities, mainly involving the corneal periphery migrating toward the center. AS-IR revealed the presence of hyporeflective dots on the cornea, suggesting that they were cystic. AS-OCT confirmed the subepithelial location of lesions. In all patients, the cornea cleared, and visual acuity recovered fully with a short course of topical steroids and lubricants. CONCLUSIONS: Mirvetuximab soravtansine therapy can cause transient corneal toxicity. A short course of topical steroids can reduce the patient symptoms.

Original languageEnglish
Pages (from-to)229-232
Number of pages4
Issue number2
Publication statusPublished - Feb 1 2019

ASJC Scopus subject areas

  • Ophthalmology


Dive into the research topics of 'Ocular Toxicity of Mirvetuximab'. Together they form a unique fingerprint.

Cite this